260P - Peritumoral vascular invasion as principal istological prognostic factor in TNBC

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Pathology/Molecular Biology
Breast Cancer
Basic Scientific Principles
Presenter Gianpiero Rizzo
Authors G. Rizzo1, V. Fregoni2, G. Daprada2, L. Pavesi2, G. Gallizzi2, I.T. Lorenzetti2, R. Tancredi2, E. Ferraris2, A. Pagani2
  • 1Oncology, Fondazione Salvatore Maugeri, 27100 - pavia/IT
  • 2Oncology Division, Fondazione Salvatore Maugeri, 27100 - pavia/IT



Triple-negative breast cancers (TNBC) is a specific histological subclass of breast cancer that has gained attention in recent years for its clinical and molecular heterogeneity with still no evidence of an optimal therapeutic strategy. Aim of this study is to identify clinical and pathological features of TNBC reviewed in our center and try to figure out prognostic factors that can drive therapeutic approach.


In this retrospective study we reviewed 127 cases of TNBC (median Age 59) that underwent surgical treatment from 2003 to 2008 analyzing the outcome (in terms of Disease Free Survival) in relation to clinical and pathologic features.


Univariate analysis performed on the entire cohort revealed that the cha Staging (P <0.0001, HR = 7.8245 [1.59-38.27]), the lympho-plasmacytic peritumoral reaction (P = 0.01, HR: 0.3160 [0.1633 to 0.6116] ), node involvment (P = 0.0241, HR: 1.9083 [1.0210 to 3.5667]) and peritumoral vascolar invasion (PVI) (P <0.0001, HR: 4.0261 [1.6608 to 9.7602]) are all prognostic factor of DFS. Multivariate analysis confirmed, in particular, PVI, observed in 24% of cases, as the main prognostic factor (P = <0.0001, HR 3.5655 [1.2-10.3]).


In the TNBC several genes involved in angiogenesis are frequently pointed out. In our hands peritumoral vascular invasion is a major prognostic factor that would identify a subgroup of TNBC with worse prognosis and therefore this would require a more aggressive therapeutic regimen with the inhibition of angiogenesis as a possible tool for the optimal treatment.


All authors have declared no conflicts of interest.